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INTRODUCTION
A clinical prognosis is an estimate of the likely course 
and outcome of a disease. In general, the type, location, 
stage, and histologic grade of the tumor are the most 
important factors that predict the outcome of cancer 
patients. Among these factors, the prognosis of solid tumors 
is greatly affected by tumor stage. However, in patients 
with hepatocellular carcinoma (HCC), prognosis assessment 
is complicated due to the biological heterogeneity of 
the disease and the lack of consensus over the best 
classification system (1, 2). To assess the prognosis of HCC 
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patients, it is recommended that the staging system take 
into consideration tumor stage, liver function, physical 
status and treatment efficacy (1, 3). Traditionally, TNM or 
Okuda classification is used for staging HCC despite some 
limitations (1, 3). The Barcelona-Clinic Liver Cancer staging 
system links staging with a specific treatment strategy and 
with an estimation of life expectancy (4). Currently, there is 
no agreement on a worldwide recommended staging system.
Biomarkers are especially useful in cancer patients in 
a number of ways, including measuring the progress of 
disease, establishing outcome, and evaluating recurrence. 
Biomarkers are measurable indicators of the severity 
or presence of some disease state and act as surrogate 
endpoints (5-8). Four technological approaches can 
provide biomarkers such as body fluid, solid tissue samples, 
physiological measurements, and imaging (8). Among 
these, imaging biomarkers have the unique benefit in that 
they distinguish the exact disease focus. They are relatively 
non-invasive and repeatable. Imaging biomarkers can be 
classified in 4 ways: diagnostic, monitoring, predictive, 
and response biomarkers (8). Despite the advances in 
imaging biomarkers in the areas of diagnosis, monitoring, 
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and response, there are only few predictive or prognostic 
imaging markers, especially in patients with HCC.
Until now it is widely accepted that tumor size, 
multifocality, and vascular invasion are the most important 
prognostic factors of HCC (9-11). These variables are 
incorporated into various staging systems, and imaging 
plays a major role in the assessment of these variables. 
Therefore, the established roles of imaging include not 
only screening and surveillance of at-risk patients, but 
also diagnosis, staging, and prognostication of HCC (12). 
For these purposes, magnetic resonance imaging (MRI) 
is advantageous because of its high soft tissue contrast, 
capacity for multiple parameters, and use of various 
contrast agents. Furthermore, in addition to the severity 
of liver disease and tumor characteristics, several other 
features related to survival have emerged from a large 
number of studies. Therefore, some magnetic resonance 
(MR) imaging features may have prognostic, as well as the 
diagnostic values (Table 1). In this review, we discuss the 
MRI features of HCC and their implications for prognosis.
Size and Multifocality
The size and number of tumors, which together represent 
tumor burden, are important prognostic factors for HCC 
(9, 10); they are included in various radiological staging 
systems (13). As tumor size increases, HCCs tend to have 
a higher frequency of vascular invasion, extrahepatic 
metastasis and a decrease in patient survival. The 
availability and success of curative treatment options, such 
as liver resection or transplantation, depends heavily on 
the size and number of HCCs. Patients with one 2–5-cm 
HCC nodule or 2 to 3 HCC nodules measuring < 3 cm, who 
have no macrovascular invasion or extrahepatic metastases, 
have priority for transplantation (14). Liver resection for 
HCCs < 3 cm in size improves long-term patient survival 
(15). However, tumors > 3 cm have a higher incidence of 
microvascular invasion, especially in tumors of “nodular 
with extranodular growth” or “confluent multinodular type” 
(16-18). For patients with small HCCs, various treatment 
options are available, and a favorable prognosis is expected. 
Small HCCs measuring < 2 cm consist of 2 distinct types: 
1) small HCCs with indistinct margins, which are considered 
“early HCC” or “HCC of vaguely nodular type” and 2) 
small HCCs with distinct margins, which are considered 
“small and progressed HCC” or “HCC of distinctly nodular 
type” (19). Histologically, early HCCs consist of well-
differentiated tumor cells (20) invading the fibrous tissue 
surrounding portal tracts, which is referred to as stromal 
invasion (21, 22). They grow by replacing the surrounding 
liver parenchyma unlike the progressed HCC (23, 24). As 
the early HCCs spread, they do not displace or destroy the 
surrounding vascular structures but replace the surrounding 
parenchyma presenting an indistinct margin (23-25). 
About 80% of small and progressed HCCs are moderately 
differentiated, and the other 20% are both well- and 
moderately-differentiated (20). Although “early HCC” 
has the least risk of microvascular invasion, “small and 
progressed HCC” is thought to exhibit vascular invasion 
and intrahepatic metastasis (26). Therefore, small HCCs of 
distinctly nodular type represent progressed cancer in spite 
of their small size. While HCCs of distinctly nodular type 
frequently show a typical enhancement pattern, HCCs of 
vaguely nodular type tend to show an atypical enhancement 
pattern such as a lack of arterial hyperenhancement or 
venous/delayed washout (27). Early HCCs frequently show 
hypo- or iso-enhancement on arterial-phase imaging, 
due to incomplete arterial neovascularization (28), and 
Table 1. Imaging Features of HCCs and Their Values
Imaging Features of HCC Diagnostic Marker Predictive Value for Tumor Differentiation Prognostic Marker
Size No No Yes
Multifocality No No Yes
Fibrous and/or pseudocapsule Yes No Yes
Intratumoral fat Yes Yes Yes
T1 hyperintensity Yes Yes No
Mosaic appearance Yes No No
Nodule-in-nodule appearance Yes Yes No
Corona enhancement Yes No Yes
Vascular invasion Yes No Yes
Signal intensity on hepatobiliary phase No Yes Yes
ADC value Yes Yes Yes
ADC = apparent diffusion coefficient, HCC = hepatocellular carcinoma
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cannot be detected reliably using extracellular agents (29). 
However, because organic anion transporting peptide (OATP) 
8 expression decreases before the sufficient arterial inflow 
during multistep hepatocarcinogenesis, early HCCs may 
appear hypointense in the hepatobiliary phase (30, 31), 
and some early HCCs are observed only in the hepatobiliary 
phase (32, 33).
More than one third of patients with HCC have multifocal 
hepatic nodules (34), which are defined as tumor 
nodules clearly separated by intervening non-neoplastic 
liver parenchyma (35). Multifocal tumors may represent 
either multiple independent HCCs arising simultaneously 
(multicentric HCC) or intrahepatic metastases from a 
primary HCC (36). Multicentric tumors may exhibit varying 
histological grade and other features, while all metastatic 
tumors of a single HCC are considered progressed lesions 
with advanced tumor grade. The prognosis of patients with 
intrahepatic metastasis from HCC tends to be worse than 
those with multicentric HCCs (37). Intrahepatic metastases 
develop by 2 different pathways. Small satellite nodules 
around the primary tumor are formed when tumor cells 
enter the portal venules that drain from the primary tumor 
and spread into the surrounding parenchyma (38, 39). 
Metastatic nodules outside the drainage area, including 
other segments or the contralateral lobe, develop via 
systemic circulation of tumor cells (40). 
Fibrous Capsule and/or Pseudocapsule
The presence of a fibrous capsule is one of the 
characteristic findings of nodular, progressed HCC (41), and 
is found in 24–90% of Asians and 12–42% of non-Asians 
with HCC (11). Since cirrhotic or dysplastic nodules (DNs) 
usually do not develop a fibrous capsule, the presence of 
a capsule is an important finding in HCC (23). Although 
some investigators have found that capsule appearance 
does not increase the diagnostic accuracy for HCC because 
it usually coincides with other hallmark imaging features, 
other investigators assert that capsule appearance is 
valuable, as it permits diagnosis of HCC without a definite 
washout appearance (14, 42). Capsule presence is regarded 
as a major diagnostic criterion for HCC, along with 
arterial hyperenhancement, according to the liver imaging 
reporting and data system (43), and Organ Procurement and 
Transplantation Network. 
Histologically, the fibrous capsule consists of an inner 
layer rich in pure, fibrous tissue and an outer layer 
containing portal venules (or sinusoids) and newly formed 
bile ducts (41, 44). The fibrous capsule is a common 
pathological feature of progressed HCC, but not of early 
HCC, DNs, or regenerative nodules (23). The fibrous capsule 
shows a thin rim of hypointensity on T1-weighted images 
and a hypointense or hyperintense rim on T2-weighted 
images (Fig. 1). On dynamic MRI, the enhancing rim shown 
Fig. 1. 55-year-old man with encapsulated progressed HCC.
A. T1-weighted three-dimensional gradient echo image with fat suppression (TR/TE/FA = 2.5 ms/1 ms/11°) in late hepatic arterial phase after 
administration of gadoxetic acid shows hyperenhancing mass with hyperemia of surrounding liver parenchyma (arrow) in segment 8. B. Mass 
is hypointense on transitional phase with thin capsule appearance (arrow). Note that relatively high enhancement of background parenchyma 
on transitional phase may obscure capsular enhancement and reduce confidence of reader. C. Fat-suppressed fast spin echo T2-weighted image 
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on portal venous or delayed phase images (45) are from 
the retention of the extracellular contrast agent within 
the prominent peritumoral sinusoids and/or fibrosis (45, 
46). On hepatobiliary contrast agent-enhanced MRI, the 
relatively high enhancement of the background liver 
parenchyma may obscure capsular enhancement during 
the late dynamic or transitional phase. Some HCCs do not 
have a true fibrous capsule even though the MRI may 
show a hypointense rim on T1-weighted and T2-weighted 
imaging (45): an enhancing rim on delayed phase images 
can mimic the fibrous capsule. Such a false-positive fibrous 
capsule, i.e., a pseudocapsule, on MRI represents prominent 
histopathological hepatic sinusoids and/or peritumoral 
fibrosis (41, 45).
Hepatocellular carcinoma with a fibrous capsule is 
considered a favorable prognostic factor, as it is associated 
with more effective transarterial chemoembolization (TACE) 
and lower recurrence rates after resection or ablation (47-
49). This may be due to the barrier effect of the fibrous 
capsule that inhibits HCC dissemination (50). HCCs with 
a pseudocapsule may also confer a favorable prognosis 
because they exhibit similar behavior in terms of vascular 
invasion and tumor grade compared to a HCC with a true 
fibrous capsule (41, 45). It is important to note that 
encapsulated HCC does not have a better prognosis than 
early-stage or small HCC, because the presence of a capsule 
indicates progressed HCC (12, 51). In other words, HCCs 
with intact capsules have a better prognosis than HCCs of 
similar grade and size without capsules or with disrupted 
capsules (41, 45, 51).
Intratumoral Fat in HCC
Hepatocellular carcinomas sometimes contain an internal 
fat component (11), which is reportedly found in up to 
19.6% of HCCs on light microscopy and in up to 10% 
of HCCs on MRI (44, 52). In patients with cirrhosis, the 
presence of intralesional fat raises concern for malignancy 
or premalignant lesions (53). Since intralesional fat is very 
rare in hepatic malignancies except for HCC, the detection 
of fat may help to exclude intrahepatic cholangiocarcinoma 
(29). Despite potential benefits, the diagnostic value of 
intralesional fat has not yet been determined. Intralesional 
fat is shown to be noncontributory in radiological 
diagnosis of HCC, as the presence of fat coincides with 
other more discriminatory imaging features, such as 
arterial hyperenhancement or delayed washout (54, 55). 
Intralesional fat can be detected by identification of a 
signal drop on opposed-phase images, compared to in-
phase, T1-weighted, chemical-shift gradient-recalled-echo 
MR images (Fig. 2) (43, 55-57). 
Intralesional fatty change or fatty metamorphosis 
occasionally occurs during hepatocarcinogenesis (53), and 
diffuse fatty metamorphosis is considered as one of the 
Fig. 2. 76-year-old man with fat-containing HCC.
A, B. Axial dual-echo gradient echo images (TR/TE = 4/1.2 ms, in-phase; 2.4 ms, opposed-phase) show mass in dome of liver. Signal loss (arrow) 
of mass on opposed-phase (B) compared to in-phase (A) indicates intralesional fat. Presence of intralesional fat permits confident diagnosis of 
HCC. HCC = hepatocellular carcinoma, TE = echo time, TR = repetition time
A B
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characteristics of early-stage HCC (52). Fatty change is most 
frequently found in HCCs with a diameter of approximately 
1.5 cm, and the prevalence decreases incrementally with 
tumor size and histologic grade. This feature is uncommon 
in HCCs > 3 cm in diameter and/or in moderately 
differentiated HCCs (25). Approximately 6% of moderately 
differentiated HCCs reportedly have fatty change, while 
no poorly differentiated HCCs exhibit this feature (52). In 
early-stage HCCs, the blood source gradually shifts from the 
vessels of the portal tracts to the newly formed non-triadal 
arteries. At this transitional stage, the lack of blood supply 
and increased cellular density may cause transient hypoxia, 
which may lead to intratumoral fatty metamorphosis 
(19, 52). However, the molecular mechanism of fatty 
metamorphosis by hypoxia in HCCs is not fully understood. 
Patients with fat-containing HCC may have a better 
clinical outcome than patients without fat-containing HCCs 
due to longer time to tumor progression and decreased risk 
of metastasis. This may be due to the fact that intralesional 
fat is characteristic of early and well-differentiated HCC, not 
of progressed HCC (58). The prognosis of progressed HCC 
with intralesional fat has not been established.
T1 Hyperintensity
Hepatocellular carcinomas may have variable signal 
intensity on T1-weighted images. Although most hepatic 
lesions are hypointense relative to liver parenchyma on T1-
weighted images, some HCCs show T1 hyperintensity (59-
62). T1 hyperintensity can be attributed to the presence 
of T1 shortening substances such as fat, copper, highly-
concentrated proteins, glycogen and hemorrhages within 
the nodules (63). 
Hepatocellular carcinomas are more commonly 
hypointense on T1-weighted images. In a previous report, 
T1 signal intensity of HCCs was hypointense in 65% of 
cases, isointense in 23%, and hyperintense in 12% (64). 
Unenhanced T1-weighted imaging plays a minor role in the 
diagnosis of HCC because HCCs and non-malignant hepatic 
lesions have various and overlapping T1 signal intensity 
(65, 66). However, the signal intensity on T1-weighted 
images may be associated with histologic grade and clinical 
outcome (59, 61). It has been previously reported that 
64–66% of HCCs of Edmondson-Steiner grade I or with 
well-differentiated histology show hyperintensity on T1-
weighted imaging (Fig. 3) (59, 61). However, the proportion 
of HCC nodules with hyperintensity on T1-weighted imaging 
gradually decreases as the histological differentiation grade 
progresses (61). Therefore, HCCs with T1 hyperintensity 
tend to have better tumor histologic grade, while HCCs 
with T1 hypointensity tend to be more poorly differentiated 
(59, 61). Besides, T1 hyperintense HCCs without T2 
hyperintensity or arterial hypervascularity usually follow a 
benign clinical course (67). 
Fig. 3. 71-year-old man with HCC showing T1 hyperintensity.
A. Unenhanced fat-saturated T1-weighted three-dimensional gradient echo image with fat suppression (TR/TE/FA = 2.5 ms/0.9 ms/11°) shows 
hyperintense mass (arrow) in segment 4. B. Mass is barely visible on fat-suppressed fast spin echo T2-weighted imaging due to isointense signal 
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Nodule-in-Nodule Appearance
Nodule-in-nodule appearance represents the presence 
of a small nodule within a larger nodule (43). This 
imaging appearance corresponds to the nodule-in-nodule 
growth pattern on histology (68) and suggests a focus 
of progressed HCC within a well-differentiated HCC or DN 
(19). Histologically, the inner nodule is composed of less 
differentiated cancer tissue, containing less fat and/or iron, 
while the parent nodule is a well-differentiated HCC or DN 
rich in fat and/or iron (69, 70). When less-differentiated 
cancerous tissues within the well-differentiated nodules 
proliferate in an expansive fashion, a ‘nodule-in-nodule’ 
appearance is frequently seen. Thus, a nodule-in-nodule 
appearance could be interpreted as a morphologic marker of 
the progression of dedifferentiation of the tumor (19, 68). 
The inner nodule, corresponding to a developing and 
distinctly nodular-type HCC, shows T2 hyperintensity, 
T1 hypointensity, and arterial enhancement on dynamic 
imaging (Fig. 4) (28, 71). On the other hand, the 
preexisting parent nodule, corresponding to either a DN 
or early HCC tissue, demonstrates T2 hypointensity, T1 
hyperintensity, and hypovascularity on dynamic imaging 
(11, 72, 73). The inner HCC nodule has radiological and 
pathologic features typical of progressed HCC with the 
potential for rapid growth and doubling time (74). However, 
consideration of the nodule-in-nodule appearance of HCC as 
a prognostic factor is not established (29). 
Corona Enhancement
Corona enhancement, one of the characteristics of 
hypervascular HCC, is described as a transient zone or 
rim of enhancement around a hypervascular HCC in the 
late arterial phase seen in either CT hepatic arteriography 
(75) or multiarterial phase dynamic MRI (Fig. 5) (63, 
76). Since corona enhancement is a very unusual finding 
other than HCC, it is one of the most reliable features for 
distinguishing HCC from other hypervascular tumors or 
pseudolesions such as arterioportal shunts (77). Because 
corona enhancement is transient, it is hard to recognize on 
routine CT or MRI. Corona enhancement is seen only in the 
perfusion phase of dynamic study, such as the arterial or 
early portal venous phases and not the equilibrium phase 
(76). This is different from capsular enhancement, which 
is mainly seen as an enhancing rim in the delayed phase 
images (76).
In addition to the ancillary imaging features, the 
importance of corona enhancement is related to blood 
drainage in HCC. The drainage vessels of HCC change during 
multistep carcinogenesis (78). As the tumor cells proliferate 
more rapidly, they first invade the intranodular hepatic 
veins; however, tumor blood drainage via intranodular and 
perinodular hepatic veins disappears early, as perinodular 
hepatic veins are collapsed by tumor compression. Then, 
venous blood from tumors begins to drain into surrounding 
hepatic sinusoids and portal veins (75, 78). In HCCs with 
a fibrous capsule, perinodular hepatic sinusoids collapse, 
Fig. 4. 56-year-old man with HCC showing nodule-in-nodule appearance.
A. Pre-contrast T1-weighted three-dimensional GRE image shows hypointense inner nodules within hyperintense outer nodule, consistent with 
nodule-in-nodule architecture. B. Subtracted arterial phase image shows hyper-enhancement of inner nodules (arrows). C. Inner nodules (arrows) 
exhibit hyperintensity relative to outer nodule and surrounding liver on fat-suppressed fast spin echo T2-weighted image. Outer nodule is 
hypointense. GRE = gradient echo, HCC = hepatocellular carcinoma
A B C
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and the fibrous capsule interrupts the connection between 
intranodular and extranodular sinusoids. Consequently, 
tumor venous blood drains into the surrounding liver 
parenchyma via portal venules within the capsule, which 
can be seen as thick corona enhancement on imaging (40, 
75, 78). Thus, corona enhancement may provide prognostic 
information. Local recurrence is frequently observed at 
the area of corona enhancement, as this corresponds to 
the initial drainage pathway of the tumor (40). The area 
of corona enhancement is the first site of intrahepatic 
metastasis of HCC, and daughter nodules are commonly 
found in this area. Therefore, resection or ablation of 
tumors should include the regions of corona enhancement 
to avoid tumor recurrence (40).
Vascular Invasion by HCC
Vascular invasion is more common in HCCs that are larger 
or of higher histologic grade (38, 79-83). Tumor cells more 
frequently involve the portal venous system than hepatic 
veins (64, 82, 84). Vascular invasion is divided into macro- 
and microvascular invasion, depending on the level of 
involved vascular structures (14). Both types of vascular 
invasion are related to poor prognosis because they provide 
the route for tumor cells to access the portal or systemic 
circulation, which can result in intrahepatic or systemic 
metastases. Thus, HCCs with vascular invasion have frequent 
multifocality and a higher recurrence rate after hepatic 
resection, ablation therapy, or liver transplantation (85, 
86). Therefore, surgical resection or liver transplantation is 
usually contraindicated in HCCs with macrovascular invasion 
(87).
It is difficult to preoperatively predict microvascular 
invasion with imaging studies as it occurs at a microscopic 
level (88). Microvascular invasion of HCC is reportedly not 
predictable using morphologic and enhancement features of 
MRI, such as T1 and T2 signal intensity, margins, presence 
of capsule or pseudocapsule, wedge-shaped peritumoral 
enhancement, or quantitative tumor enhancement (18, 76). 
However, several tumor characteristics on MRI have been 
suggested as markers for risk of microvascular invasion. 
Morphologically, tumors with more than 3 foci and a tumor 
size > 3 cm exhibiting gross patterns of “nodular with 
extranodular growth”, “confluent multinodular type”, or 
“infiltrative type” are reported to be closely related to 
microvascular invasion (16-18). Therefore, multiple tumors 
or tumors > 3 cm with non-smooth margins on MRI are 
likely to have microvascular invasion. Additionally, HCCs of < 
2 cm, especially those of distinct nodular type, may exhibit 
microvascular invasion (32). These tumors usually show a 
typical dynamic enhancement pattern and hyperintensity 
on T2-weighted and diffusion-weighted images (32). Some 
studies have suggested that large or irregular and distorted 
corona enhancement in HCC may predict microvascular 
invasion (76, 89-91). However, this finding is not been 
validated by other studies. Peritumoral hypointensity and 
Fig. 5. 66-year-old man with HCC showing corona enhancement.
A, B. T1-weighted three-dimensional GRE image with fat suppression (TR/TE/FA = 4.5 ms/2.1 ms/15°) in (A) early and (B) late hepatic 
arterial phase after administration of gadolinium-based contrast agent shows hyper-enhancing mass (arrow) in segment 6. Notice irregular 
circumferential enhancement (arrow) in liver parenchyma around mass in late hepatic arterial phase. C. Enhancement of perilesional parenchyma 
fades in portal venous phase. Transient enhancement of perilesional parenchyma is known as corona enhancement. Note capsular appearance of 
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non-smooth tumor margins on the hepatobiliary phase 
of gadoxetic acid-enhanced MRI may also be indicative 
factors of microvascular invasion (Fig. 6) (17, 91). In 
areas of peritumoral hypointensity of the liver parenchyma, 
expression of OATPs and canalicular transporter multidrug 
resistance-associated protein 2 receptors decrease, probably 
because of hemodynamic alteration related to tumor 
obstruction of minute portal veins (17). The tumor margin 
may be non-smooth if the tumor is infiltrative or with a 
minute budding portion at its periphery (91). 
Organic Anion Transporter Polypeptide 
Expression and Signal Intensity on 
Hepatobiliary Phase Imaging
Gadoxetic acid and gadobenate dimeglumine are 2 
hepatobiliary contrast agents, currently available in clinical 
practice (12). They behave like extracellular agents after 
injection, are taken up by functioning hepatocytes and 
excreted into the biliary system. OATP 8 (also known as 
OATP1B1/3) is thought to be responsible for uptake of 
hepatobiliary contrast agents by hepatocytes (92, 93). 
Thus, nodules with low or no OATP expression do not 
take up hepatobiliary agents and appear hypointense in 
the hepatobiliary phase, while nodules with preserved or 
elevated OATP 8 expression take up the agents and tend to 
be isointense or hyperintense. 
The expression of these transporters decreases during 
hepatocarcinogenesis. Expression levels are high in 
regenerating nodules and low-grade DNs and are lower in 
many high-grade DNs, early HCCs, and progressed HCCs 
(92, 94). On the hepatobiliary phase of gadoxetic acid-
enhanced MRI, HCCs are usually hypointense from the 
lack of gadoxetic acid uptake due to down regulation of 
OATP 8 expression (95, 96). Studies have shown that the 
degree of tumor enhancement in the hepatobiliary phase 
after injection of gadoxetic acid inversely correlates with 
histologic grades (92, 97). Poorly-differentiated tumors 
tend to show lower signal intensity, as compared to well-
differentiated or moderately-differentiated ones. Inverse 
correlation has been associated to the gradual decline in 
OATP expression seen during hepatocarcinogenesis (92, 
94). This suggests that quantitative analysis of tumor 
enhancement in the hepatobiliary phase may predict 
histologic and prognostic features (92). However, other 
researchers show that the degree of tumor enhancement 
does not correspond with tumor grades (95, 98) or only 
correlates in a subset of patients with preserved liver 
function (99). 
Some HCCs show hyperintensity on hepatobiliary 
phase due to increased uptake of hepatobiliary contrast 
media (Fig. 7) (100-103). The overexpression of OATP 8 
in some HCCs may be due to genomic alteration during 
hepatocarcinogenesis (92). The prevalence of these 
hyperintense HCCs on hepatobiliary phase varies from 5 to 
12% (100-102). Most patients have well- or moderately-
differentiated tumors, but poor differentiation is observed 
rarely (92, 95, 97, 100, 102, 103). Thus, the hyperintensity 
of HCCs on hepatobiliary phase may not be dependent on 
histologic differentiation of the tumor, but rather on the 
degree of OATP 8 expression or other potential genomic 
alterations (94, 97, 104). 
Hyperintense HCCs on hepatobiliary phase may indicate 
a favorable clinical outcome in patients (95) since these 
tumors have infrequent microvascular invasion and have a 
longer interval of recurrence, as compared with hypointense 
HCCs (95, 102, 104, 105). Moreover, hyperintense HCCs 
most commonly appear as expanding gross-type, not 
Fig. 6. 51-year-old man with HCC and microvascular invasion.
A. Gadoxetic acid-enhanced T1-weighted three-dimensional GRE sequence (TR/TE/FA = 3.4 ms/1.7 ms/15°) acquired in late hepatic arterial phase 
shows heterogeneous mass at segment 8 of liver. B. Transitional phase image at three minutes depicts hypointense mass. C. Margin of mass is 
non-smooth or lobulated on hepatobiliary phase imaging acquired 20 minutes after injection (arrow). D. Gross pathology photograph of resected 
specimen reveals confluent, multinodular type HCC. Histopathologic examination proves frequent microvascular invasion. FA = flip angle, GRE = 
gradient echo, HCC = hepatocellular carcinoma, TE = echo time, TR = repetition time
A B C D
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infiltrative or diffuse-type, which are prone to poor 
prognosis (95). Patients with iso- to hyperintense HCCs on 
hepatobiliary phase tend to have lower levels of prognostic 
serum tumor markers (a-fetoprotein, protein induced by 
vitamin K absence or antagonist-II [PIVKA-II]) (104, 106, 
107). Hyperintense HCCs on hepatobiliary phase are more 
common in older patients, suggesting that they grow more 
slowly (95, 98, 100, 103). 
Correlation of MR Imaging and 
Immunohistochemical Markers
Prognosis is not easy to determine in patients with HCC 
due to the heterogeneous nature of the tumors and the 
lack of appropriate biomarkers. Despite the advancement 
of molecular medicine, there are no well-established 
biomarkers to predict prognosis of HCC. Currently used 
tumor markers in HCC, such as alpha-fetoprotein or PIVKA-
II, have limited sensitivity and specificity; however, some 
immunohistochemical markers have the potential to be used 
for prognosis and treatment stratification. 
Hepatocellular carcinomas with biliary phenotypic 
markers such keratin 7 and keratin 19 (K19) may be 
more aggressive and have a worse prognosis (108, 109). 
Some HCCs expressing progenitor cell markers, such as 
epithelial cell adhesion molecule (EpCAM) and K19 have 
Fig. 7. 64-year-old man with HCC showing hyperintensity in hepatobiliary phase.
A. Gadoxetic acid-enhanced T1-weighted three-dimensional GRE image (TR/TE/FA = 3.4 ms/1.7 ms/15°) in late arterial phase shows exophytic, 
hyperenhancing mass (arrow) in left posterior liver. B. In hepatobiliary phase, mass is hyperintense with central hypointense areas (arrow). FA = 
flip angle, GRE = gradient echo, HCC = hepatocellular carcinoma, TE = echo time, TR = repetition time
A B
Fig. 8. 51-year-old man with HCC.
A. Hepatobiliary phase image acquired 20 minutes after injection shows hypointense nodule in segment 7 of liver (arrow). B. Nuclear grade III 
trabecular and pseudoglandular HCC with hepatic cells was confirmed (hematoxylin and eosin staining, x 100). C. Immunoreactivity of keratin 19 
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aggressive clinical outcomes due to a higher recurrence 
rate after resection or liver transplantation, resistance to 
chemoradiation therapy, and a higher rate of metastases 
(24, 108-117). It is reported that HCCs expressing EpCAM 
or K19 show different radiologic features on MRI, as 
compared with HCCs lacking these markers (Fig. 8) (110). 
Gross multinodular confluent- or infiltrative-type tumors 
that are associated with an unfavorable prognosis are more 
common (110). A progressive or persistent enhancement 
pattern on dynamic study, similar to the enhancement 
pattern of cholangiocarcinoma, is more frequently seen in 
HCCs expressing progenitor cell markers (110). On gadoxetic 
acid-enhanced MRI, K19 expression is inversely correlated 
with tumor enhancement of HCC on hepatobiliary phase. 
Therefore, tumor enhancement on hepatobiliary phase is 
lower in K19-positive HCCs than in K19-negative HCCs (110, 
118). 
Diffusion-Weighted Imaging
One of the characteristic radiologic features of many 
malignant tumors is elevated signal intensity on diffusion-
weighted imaging, caused by a reduced apparent diffusion 
coefficient (ADC) of water in the tumor microenvironment 
(Fig. 9) (119). The mechanism of reduced ADC is not 
completely understood, but may reflect greater diffusion 
hindrance and reduced mobility of water molecules due to 
decreased extracellular space and increased tortuosity of 
the extracellular space matrix (120-123). Most but not all 
(124) studies show that the addition of diffusion-weighted 
imaging to MRI improves the detection of HCC (125-127) 
and intrahepatic HCC metastases (128). The ADC value may 
provide information on tumor behavior. Since cellularity and 
the nuclear-to-cytoplasmic (N/C) ratio are major features 
used to determine histologic grading, high-grade tumors 
have densely-packed cells and a high N/C ratio in general. 
Densely-packed tumor cells can inhibit effective motion of 
water molecules and can restrict diffusion. Thus, the ADC 
value and the appearance on diffusion-weighted imaging 
likely reflect tumor cellularity and microenvironment.
Some studies suggest that measuring the ADC value 
can predict tumor histopathologic grade (129-133), 
microvascular invasion (88), the presence of progenitor cell 
markers (110), and early recurrence after resection (132). 
However, these correlations are not always consistent, 
and some studies show no significant correlation between 
ADC and histopathologic grade of HCCs due to the large 
overlap of ADC among different histopathologic grades 
(134). Because the ADC value and diffusion-weighted signal 
intensity ratios particularly depend on techniques, magnetic 
field strength, and MRI scanners, diffusion-weight-based 
prediction thresholds may not yet be generalized. 
Fig. 9. 63-year-old man with HCC showing restricted diffusion.
A. Gadoxetic acid-enhanced T1-weighted three-dimensional GRE sequence (TR/TE/FA = 3.4 ms/1.7 ms/15°) in late arterial phase shows 
hyperenhancing mass (arrow) in right lobe of liver. B. Apparent diffusion coefficient map shows hypointensity (arrow) suggesting restricted 
diffusion. Restricted diffusion is highly suggestive of malignancy, but is not specific for HCC. FA = flip angle, GRE = gradient echo, HCC = 
hepatocellular carcinoma, TE = echo time, TR = repetition time
A B
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Diffusion-weighted imaging is used to monitor efficacy 
of treatment using TACE and target therapy (135-140). 
Some studies report that the ADC value of HCCs increase 
after TACE (136-138), and a high baseline ADC value could 
predict poor response to TACE (135, 140). In HCCs treated 
with an antiangiogenic agent (sorafenib), the ADC value 
may temporarily decrease in the early phase of treatment 
and increase again in long-term follow-up (> 3 months) 
(139). However, ADC values vary widely and may not 
contribute to the accurate diagnosis of tumor necrosis by 
any cut-off levels. Increased ADC may be caused not only by 
tumor necrosis, but also by perilesional inflammation and 
arterial reperfusion after TACE (141).
CONCLUSION
MRI can not only be used for non-invasive diagnosis and 
staging, but also for predicting tumor biology as an imaging 
biomarker in patients with HCC. Favorable findings of HCCs 
on MRI include small size, presence of fibrous capsule/
pseudocapsule, intralesional fat, high ADC value, and 
smooth margins or hyperintensity on hepatobiliary phase 
images, while unfavorable findings of HCCs include large 
size, multifocality, low ADC value, non-smooth margins or 
hypointensity on hepatobiliary phase images. 
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